Molecular Cancer Therapeutics

Aims & Scope

Molecular Cancer Therapeutics will focus on basic research that has implications for cancer therapeutics in the following areas: Experimental Cancer Therapeutics, Identification of Molecular Targets, Targets for Chemoprevention, New Models, Cancer Chemistry and Drug Discovery, Molecular and Cellular Pharmacology, Molecular Classification of Tumors, and Bioinformatics and Computational Molecular Biology.

The journal provides a publication forum for these emerging disciplines that is focused specifically on cancer research.

Papers are stringently reviewed and only those that report results of novel, timely, and significant research and meet high standards of scientific merit will be accepted for publication.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	5.5
2024	5.30

SJR (SCImago Journal Rank)

Year	Value
2024	2.493

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	206

Journal Rank

Year	Value
2024	962

Journal Citation Indicator

Year	Value
2024	2980

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology and Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

  Citation: 1860

  Authors: Sandip Pravin, Razelle

• Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

  Citation: 1854

  Authors: Aaron M., Shumei, Lyudmila, Sandip P., Garrett M., Vincent, Philip J., Gregory A., Razelle

• Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

  Citation: 1169

  Authors: Scott M., Lila, Philippa, Augusto, Josep M., Mark

• Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

  Citation: 1104

  Authors: F. Michael, Jason, Jenny, Kyoko, Yongchang, Peiwen, Fawn, Felix, Frauke, Belinda, Jessica, Andrew, A. Douglas, Stefan, Lillian, Justin, Yu-Chien, Alison H.

• Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts

  Citation: 1071

  Authors: David W., Patricia J., Paul R., William L., MaryAnne, Erin, Mudher, XianXian, Wilbur R., Nancy K., Peter L.

• The Role of Autophagy in Cancer: Therapeutic Implications

  Citation: 1005

  Authors: Zhineng J., Cheng E., Shengbing, Frank A.

• Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity

  Citation: 968

  Authors: Sauveur-Michel, Frédéric, Josef, Pascal, Christian, Christine, Saskia, Patrick, Alain, Kevin, Doriano, Daniela, Marjo, Leon, Peter, William, Carlos

• Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer

  Citation: 885

  Authors: Matt I., Susan D., Jennifer B., Lijing, Tania, Bindu, Julie R., Guy J., Evan R., Jim, Andrew L., Francesco, Mirna L.M., Peter J., Eric B., Timothy F., Taotao, Jinfu, Frances, Mark K.

• MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs<i>In vitro</i>and<i>In vivo</i>

  Citation: 808

  Authors: Hiroshi, Hiroshi, Yoko, Katsuyoshi, Shunsuke, Kyoko, Yoko, Harold, Pradip K., Bo-Sheng, Hidehito

• Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

  Citation: 670

  Authors: Junko, Shar-Yin N., Amèlie, Yiping, Jiuping, Shunichi, Joel, Beverly, James H., Yves

---